pyrimidin-2-one beta-ribofuranoside has been researched along with Leukemia, Myeloid, Acute in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abd Elmageed, ZY; Ali, HEA; Buttolph, T; Carraway, HE; Cen, Y; Denvir, J; Fan, J; Fandy, TE; Malkaram, SA; Primerano, DA; Shatnawi, A | 1 |
| Batz, C; Claus, R; Flotho, C; Ihde, S; Lübbert, M; Niemeyer, CM; Plass, C; Sandrock, I; Schneider, M | 1 |
2 other study(ies) available for pyrimidin-2-one beta-ribofuranoside and Leukemia, Myeloid, Acute
| Article | Year |
|---|---|
Activation of SIRT6 by DNA hypomethylating agents and clinical consequences on combination therapy in leukemia.
Topics: Acetylation; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Marrow; Cell Line, Tumor; Cytidine; Decitabine; DNA Methylation; Histones; Humans; Leukemia, Myeloid, Acute; Sirtuins | 2020 |
The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Cytidine; Decitabine; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Myeloid, Acute | 2009 |